Pozen (POZN +3.9%) gains after saying it's sold most of the future royalty and milestone...

|By:, SA News Editor

Pozen (POZN +3.9%) gains after saying it's sold most of the future royalty and milestone payments under its licensing agreement with Glaxo Group covering Treximet sales in the United States, to a financial investor for $75M.